Cargando…

Peroxisome Proliferator-Activated Receptor-gamma agonists exhibit anti-inflammatory and antiviral effects in an EcoHIV mouse model

The widespread use of combination antiretroviral therapy (cART) has resulted in significantly reduced deaths from HIV-1 associated complications and opportunistic infections. However, it is estimated that up to 50% of HIV-1 infected individuals still develop HIV-1 associated neurocognitive disorders...

Descripción completa

Detalles Bibliográficos
Autores principales:	Omeragic, Amila, Kara-Yacoubian, Nareg, Kelschenbach, Jennifer, Sahin, Cigdem, Cummins, Carolyn L., Volsky, David J., Bendayan, Reina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603270/ https://www.ncbi.nlm.nih.gov/pubmed/31263138 http://dx.doi.org/10.1038/s41598-019-45878-6

Ejemplares similares

Protocol for optimizing production and quality control of infective EcoHIV virions
por: Alfar, Hammodah R., et al.
Publicado: (2023)

Buprenorphine reverses neurocognitive impairment in EcoHIV infected mice: A potential therapy for HIV-NCI
por: Murphy, Aniella J., et al.
Publicado: (2022)

EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment
por: Gu, Chao-Jiang, et al.
Publicado: (2018)

Intranasal insulin therapy reverses hippocampal dendritic injury and cognitive impairment in a model of HIV-associated neurocognitive disorders in EcoHIV-infected mice
por: Kim, Boe-Hyun, et al.
Publicado: (2019)

Peroxisome proliferator-activated receptor-gamma: potential molecular therapeutic target for HIV-1-associated brain inflammation
por: Omeragic, Amila, et al.
Publicado: (2017)

Glutamine antagonist JHU083 improves psychosocial behavior and sleep deficits in EcoHIV-infected mice
por: Bell, Benjamin J., et al.
Publicado: (2022)

Disrupted Decision-Making: EcoHIV Inoculation in Cocaine Dependent Rats
por: McLaurin, Kristen A., et al.
Publicado: (2022)

Potential pharmacological approaches for the treatment of HIV-1 associated neurocognitive disorders
por: Omeragic, Amila, et al.
Publicado: (2020)

Implication of the Autophagy-Related Protein Beclin1 in the Regulation of EcoHIV Replication and Inflammatory Responses
por: Rodriguez, Myosotys, et al.
Publicado: (2023)

A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice
por: Tomusange, Khamis, et al.
Publicado: (2016)

Prevention and treatment of HIV infection and cognitive disease in mice by innate immune responses
por: Dong, Baojun, et al.
Publicado: (2020)

Peroxisomes and Innate Immunity: Antiviral Response and Beyond
por: Ferreira, Ana Rita, et al.
Publicado: (2019)

CCL2 is required for initiation but not persistence of HIV infection mediated neurocognitive disease in mice
por: Kim, Boe-Hyun, et al.
Publicado: (2023)

The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
por: Thomas, M. C., et al.
Publicado: (2012)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

Amphipathic DNA polymers exhibit antiviral activity against systemic Murine Cytomegalovirus infection
por: Cardin, Rhonda D, et al.
Publicado: (2009)

Peroxisome Proliferator-Activated Receptor Agonists: Do They Increase Cardiovascular Risk?
por: Aljada, Ahmad, et al.
Publicado: (2009)

Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders
por: Sagheddu, Claudia, et al.
Publicado: (2021)

Enhanced Hepatocarcinogenicity Due to Agonists of Peroxisome Proliferator-Activated Receptors in Senescent Rats: Role of Peroxisome Proliferation, Cell Proliferation, and Apoptosis
por: Youssef, Jihan, et al.
Publicado: (2002)

Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ
por: McCormick, David L., et al.
Publicado: (2015)

Synergy between peroxisome proliferator‐activated receptor γ agonist and radiotherapy in cancer
por: Huang, Guodong, et al.
Publicado: (2018)

Metabolites of endophytic fungi isolated from leaves of Bauhinia variegata exhibit antioxidant activity and agonist activity on peroxisome proliferator-activated receptors α, β/δ and γ
por: Mesquita, Pedro Góes, et al.
Publicado: (2022)

Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
por: Fruchart, Jean-Charles
Publicado: (2013)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Viperin interacts with PEX19 to mediate peroxisomal augmentation of the innate antiviral response
por: Khantisitthiporn, Onruedee, et al.
Publicado: (2021)

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives
por: Chiarelli, Francesco, et al.
Publicado: (2008)

Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: a link to chemokines?
por: Freitag, Caroline M., et al.
Publicado: (2014)

Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver
por: Zhu, Yun-Xia, et al.
Publicado: (2016)

Treatment of experimental autoimmune uveoretinitis with peroxisome proliferator-activated receptor α agonist fenofibrate
por: Osada, Miho, et al.
Publicado: (2014)

Antitumor action of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone in hepatocellular carcinoma
por: BO, QI-FU, et al.
Publicado: (2015)

Peroxisome Proliferator Activated Receptor Agonists Modulate Transposable Element Expression in Brain and Liver
por: Ferguson, Laura B., et al.
Publicado: (2018)

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
por: Heudobler, Daniel, et al.
Publicado: (2018)

Peroxisome Proliferator-Activated Receptor Beta/Delta Agonist Suppresses Inflammation and Promotes Neovascularization
por: Tobita, Yutaro, et al.
Publicado: (2020)

Effects of Selective Peroxisome Proliferator Activated Receptor Agonists on Corneal Epithelial Wound Healing
por: Tobita, Yutaro, et al.
Publicado: (2021)

Structural Biology-Based Exploration of Subtype-Selective Agonists for Peroxisome Proliferator-Activated Receptors
por: Miyachi, Hiroyuki
Publicado: (2021)

Peroxisome proliferator-activated receptor gamma and its natural agonists in the treatment of kidney diseases
por: Sharma, Vinesh, et al.
Publicado: (2022)

Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs
por: Nwabufo, Chukwunonso K., et al.
Publicado: (2022)

Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
por: Wang, Limei, et al.
Publicado: (2014)

Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism
por: Lee, Mi Young, et al.
Publicado: (2012)

Effects of Peroxisome Proliferator-Activated Receptor-δ Agonist on Cardiac Healing after Myocardial Infarction
por: Park, Jeong Rang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dm91vul3g8hb8rqdf52j5loo9p